Methamphetamine use disorder (MUD) remains one of the most underserved disorders in addiction medicine, largely because there are no FDA-approved medications for its treatment—yet. The 2024 National ...

Methamphetamine (MA) use disorder poses a significant public health challenge, particularly given the rise in MA-involved overdoses over the past decade. Despite the severity of this issue, there is ...

Though overdose deaths continue to surge, there is no approved medication to treat methamphetamine use disorder. Now, an experimental two-drug therapy has yielded promising results, UCLA researchers ...

A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, UCLA-led research suggests.

There has been an "alarming" increase in mental health hospital admissions involving methamphetamine use, new research showed. Investigators found that between 2008 and 2020, such admissions increased ...

A prescription medication used to treat attention deficit hyperactivity disorder (ADHD) could be repurposed as the first pharmacotherapy for people with methamphetamine dependence, according to a ...

A phase 2 trial evaluating CS-1103 in participants with methamphetamine use disorder is expected to begin in the first quarter of 2026. The Food and Drug Administration (FDA) has granted Fast Track ...

A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, UCLA-led research suggests.

Reducing stimulant use was associated with significant improvement in measures of health and recovery among people with stimulant use disorder, even if they did not achieve total abstinence. This ...